These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31677266)

  • 1. Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.
    McKay SL; Guo A; Pergam SA; Dooling K
    Clin Infect Dis; 2020 Oct; 71(7):e125-e134. PubMed ID: 31677266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
    Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
    Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
    Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
    Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program.
    Gans H; Chemaly RF
    BMC Infect Dis; 2021 Jan; 21(1):46. PubMed ID: 33430796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes zoster: diagnostic, therapeutic, and preventive approaches.
    Bader MS
    Postgrad Med; 2013 Sep; 125(5):78-91. PubMed ID: 24113666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
    Sullivan KM; Farraye FA; Winthrop KL; Willer DO; Vink P; Tavares-Da-Silva F
    Vaccine; 2023 Jan; 41(1):36-48. PubMed ID: 36460534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
    Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
    Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
    [No Abstract]   [Full Text] [Related]  

  • 10. Herpes Zoster and Postherpetic Neuralgia: Changing Incidence Rates From 1994 to 2018 in the United States.
    Thompson RR; Kong CL; Porco TC; Kim E; Ebert CD; Acharya NR
    Clin Infect Dis; 2021 Nov; 73(9):e3210-e3217. PubMed ID: 32829399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients.
    Racine É; Gilca V; Amini R; Tunis M; Ismail S; Sauvageau C
    Vaccine; 2020 Sep; 38(40):6205-6214. PubMed ID: 32788132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014.
    Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Orrico-Sánchez A
    BMC Infect Dis; 2020 Nov; 20(1):905. PubMed ID: 33256624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
    Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V
    BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
    Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
    J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hospitalizations and Emergency Department Visits for Herpes Zoster in Immunocompromised and Immunocompetent Adults in Ontario, Canada, 2002-2016.
    Buchan SA; Daneman N; Wang J; Garber G; Wormsbecker AE; Wilson SE; Deeks SL
    Clin Infect Dis; 2020 Jun; 71(1):22-29. PubMed ID: 31436814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.
    Yawn BP; Saddier P; Wollan PC; St Sauver JL; Kurland MJ; Sy LS
    Mayo Clin Proc; 2007 Nov; 82(11):1341-9. PubMed ID: 17976353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.
    Sahoo F; Hill JA; Xie H; Leisenring W; Yi J; Goyal S; Kimball LE; Lee I; Seo S; Davis C; Pergam SA; Flowers ME; Liaw KL; Holmberg L; Boeckh M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):505-511. PubMed ID: 28039754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors for herpes zoster following heart transplantation.
    Koo S; Gagne LS; Lee P; Pratibhu PP; James LM; Givertz MM; Marty FM
    Transpl Infect Dis; 2014 Feb; 16(1):17-25. PubMed ID: 24147978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.